Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

NCT07724223 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (CRC)

Interventions

DRUG: Fruquintinib plus Cetuximab-beta

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences